EAA171/
The OPTIMUM Trial
A clinical trial opportunity for patients with multiple myeloma after lenalidomide maintenance therapy following stem cell transplant
**The OPTIMUM trial (EAA171)** is for patients who have received an autologous stem cell transplant for their multiple myeloma diagnosis and who are found to have detectable myeloma after at least 6 months of maintenance treatment with lenalidomide pills

- Minimal Residual Disease (MRD) testing of bone marrow allows doctors to identify those patients with persistent disease who may be at risk of their cancer returning sooner
- All patients who have evidence of myeloma persistence (M-protein in the blood or urine, or cells MRD-positive in the marrow) who enroll in OPTIMUM will continue on lenalidomide maintenance therapy, as this is the usual care you would receive. Additionally, half of the patients will be assigned by chance to receive the study drug called ixazomib once a week (also a pill)
- Results from the two groups will be compared to see if adding ixazomib lengthens the life of patients compared to the usual approach
- If you decide to participate in EAA171/OPTIMUM, your doctor will continue to follow your condition for up to 10 years and watch you for side effects as well as your overall health

*To learn more*, ask your doctor, or:

- Visit [www.ecog-acrin.org](http://www.ecog-acrin.org) and search EAA171, then select the link to the EAA171 Home Page. To find medical facilities where this trial is open, scroll down the page to Locations & Contacts and click the + sign
- Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)

**Reminder:** Please follow-up with your doctor 11 months after your transplant! Date: ________________